ten23 health obtains “Pending B Corp.” status and joins both the Swiss Triple Impact Directory and the United Nations Global Compact (UN GC) programme
ten23 health, a global contract development and manufacturing organisation (CDMO) has achieved various milestones on its journey towards being a leading fair and sustainable pharmaceutical service provider.
As of today, ten23 health becomes a “Pending B Corporation,” which means that the company meets the legal accountability requirement for B Corp. Certification and takes measures to manage its social and environmental performance.
Pending B Corp. status is valid for a non-renewable 1-year term, after which ten23 health aims to obtain the full B Corp. Certification.
B Corp. Certification is a designation that a business meets high standards of verified performance, accountability and transparency on factors from employee benefits and charitable giving to supply chain practices and input materials.
To achieve the full B Corp. Certification, a company must demonstrate high social and environmental performance, integrate commitments to stakeholders into company governing documents and exhibit transparency on performances versus B Lab’s standards.
In addition, ten23 health also announced that it has completed the Swiss Triple Impact (STI) programme, following the three-step pathway for concrete commitments related to the UN Sustainable Development Goals (SDGs) and becomes a listed STI Directory member.
The STI Directory is one of the largest listings of Swiss organisations to have taken bold and concrete commitments to contribute to the SDGs and the 2030 Agenda.
ten23 health has also joined the United Nations Global Compact (UN GC) programme, the world’s largest corporate sustainability initiative, aligning company strategies and operations with universal principles on human rights, labour, environment and anticorruption, and taking actions that advance societal goals.